Background {#Sec1}
==========

Shoulder pain is a feeling of stiffness or discomfort around the shoulder joint, especially in the trapezius muscle. The incidence of shoulder pain in primary care is 14.7 per 1000 patients per year, and approximately 70% of the population experiences more than one episode in a lifetime \[[@CR1]--[@CR3]\]. Electrotherapy (transcutaneous electrical nerve stimulation, TENS), ultraviolet therapy, hot pack, massage, and sodium channel blocker drugs are used to alleviate muscle contractions; however, these interventions are largely ineffective \[[@CR4], [@CR5]\]. The tension in the shoulder muscles worsens with prolonged sitting at a computer and improper posture, and under physical and emotional stress. Myalgia is caused by the accumulation of lactic acid in the muscles and impaired blood circulation. In traditional East Asian medicine, muscle cramps and chronic musculoskeletal pain are considered to be due to blood stasis and can lead to limitations in shoulder movements by blocking the meridians \[[@CR6]\].

Blood stasis is defined as the pathological stagnation of blood in certain parts of the body. It manifests as a variety of symptoms, including pain in a fixed location, a dark-purple appearance of the face or tongue, bleeding, blood spots under the skin, and an astringent pulse \[[@CR7]\]. It is believed that blood stasis causes lipoprotein disorders such as thrombosis and the formation of atheromatous plaques \[[@CR8]--[@CR10]\]. Several herbal formulae that reduce blood stasis are helpful in the management of metabolic disorders \[[@CR11]\]. Furthermore, blood stasis can occur after physical injuries, and the use of herbal medicine to eliminate blood stasis has been reported to alleviate muscle pain in some cases \[[@CR12]\].

Therefore, we hypothesised that Gyejibongnyeong-Hwan (GBH), a herbal formula for dissipating blood stasis, is effective for the treatment of shoulder pain and hyperlipidaemia. GBH was approved as a medicine for shoulder discomfort by the Ministry of Food and Drug Safety (MFDS), South Korea \[[@CR13]\]. In previous studies, GBH has been reported to ameliorate metabolic diseases such as hyperglycaemia and hyperlipidaemia \[[@CR14], [@CR15]\]. The primary objective of this pilot trial is to explore whether GBH relieves shoulder pain related to blood stasis. The secondary objective is to determine whether GBH is also helpful in improving blood lipid levels associated with blood stasis.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is a multi-centre, randomised, wait-list controlled pilot study. This study will determine the effectiveness of GBH by comparing two groups: the immediate GBH treatment group and the waiting treatment group. Furthermore, the findings before and after GBH treatment will be compared in each group. The immediate treatment group will undergo an 8-week treatment period and an 8-week follow-up period. The waiting treatment group will undergo an 8-week waiting period and an 8-week treatment period. An overview of the trial process is shown in Fig. [1](#Fig1){ref-type="fig"}. Fig 1Flow chart of the trial process. GBH Gyejibongnyeong-Hwan

Setting {#Sec4}
-------

This trial will be conducted at two hospitals: Chungju Oriental Hospital of Semyung University and Jecheon Oriental Hospital of Semyung University. This study was sponsored by Korea Institute of Oriental Medicine (KIOM), and KIOM wrote the protocol following the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist (Additional file [1](#MOESM1){ref-type="media"}). Both centres will be managed by KIOM during the study period.

Recruitment {#Sec5}
-----------

Patients with shoulder pain and blood stasis will be recruited over 6 months at Chungju Oriental Hospital of Semyung University and Jecheon Oriental Hospital of Semyung University. Posters will be posted publicly inside and outside both hospitals. Anyone interested in the study can contact the clinical research coordinator (CRC) of each site via telephone or e-mail. Then, a Korean medical doctor will screen participants for eligibility. Those who agree to participate in the study and provide written informed consent will be enrolled.

Inclusion and exclusion criteria {#Sec6}
--------------------------------

The following participants will be included in this trial: those having physical strength, cold feet, and shoulder pain and a visual analogue scale (VAS) score of 4 or higher out of 10; those with a blood stasis score of 9 or higher (15-item questionnaire for diagnosis of blood stasis with metabolic diseases) ([Appendix](#Sec19){ref-type="sec"}: Table 2); triglyceride (TG) level of ≥150 mg/dl or total cholesterol (TC) level of ≥200 mg/dl; and those who voluntarily agree to participate in this study and will comply with the restriction during the study period.

The following patients were excluded: those who are unable to give informed consent by themselves; pregnant women (for women of child-bearing age, the human chorionic gonadotropin (HCG) level will also be measured before GBH administration); those participating in another clinical trial; and those receiving medicines for therapeutic purposes.

Randomisation, allocation, and blinding {#Sec7}
---------------------------------------

Participants meeting the inclusion and exclusion criteria will be randomly allocated to either the immediate treatment group or the waiting treatment group at a ratio of 1:1. A computer-generated randomisation schedule based on a table of random digits will be used for group assignment. Access to the sequence will be restricted to the KIOM data manager (who is independent of the study team). The randomisation sequence will be included in a password-protected computer file and allocated to each hospital by an investigator.

Since this is an open-label trial without placebo, neither researchers nor participants will be blinded.

Intervention {#Sec8}
------------

The immediate treatment group will receive GBH for 8 weeks on enrolment, and the waiting treatment group will receive GBH for 8--16 weeks at 8 weeks after enrolment. Every participant will receive 3.0 g of GBH (Hanpoong Pharm & Food Co., Ltd) twice a day for 8 weeks. GBH is a light-brown granular substance consisting of Cinnamomi Ramulus, *Wolfiporia extensa*, *Paeonia suffruticosa* Andrews, *Prunus persica*, and *Paeonia lactiflora* in an equal ratio. Any other medicine or treatment that may affect shoulder pain and hyperlipidaemia will be prohibited during the study period.

Sample size {#Sec9}
-----------

This trial is a pilot study that examines the feasibility of conducting a large-scale randomised clinical trial for the use of GBH to treat shoulder pain related to blood stasis. No adequate references could be found with regard to the sample size; hence, a sample size of 40 patients is determined to be adequate considering a 25% drop-out rate. Participants will be assigned to either the immediate treatment group or the waiting treatment group at a ratio of 1:1.

Data collection {#Sec10}
---------------

The following demographic data will be collected on the enrolment date: age, sex, occupation, height, weight, alcohol habit, and smoking status. Blood tests and blood stasis questionnaire evaluation will be conducted and VAS scores for shoulder pain will be assessed during the screening visit. After randomisation, the ankle--brachial pressure index (ABI), brachial--ankle pulse wave velocity (baPWV), oxygen saturation (SpO~2~), total haemoglobin (SpHb), pleth variability index (PVI), oxygen content (SpOC), pulse rate (PR), methaemoglobin (SpMet), perfusion index (PI), blood pressure (BP), body mass index (BMI), and waist circumference (WC) will be assessed (visit 1). Blood tests, blood stasis questionnaire evaluation, and VAS score evaluation will be conducted again during visit 1 in the waiting treatment group since the subjects are required to wait for 8 weeks after randomisation. SpO~2~, SpHb, PVI, SpOC, PR, SpMet, and PI will be measured using an oximeter (Masimo Corp.). Blood tests, blood stasis questionnaire evaluation, and oximeter measurements will be performed and shoulder pain, ABI, baPWV, BP, BMI, and WC will be assessed every 4 weeks after GBH has been received (visits 2 and 3). Furthermore, compliance and adverse events will be assessed every 4 weeks (visit 2 and 3), and patient satisfaction will be evaluated after 8 weeks of intervention (visit 3). At the follow-up visit in the immediate treatment group, blood tests, blood stasis questionnaire evaluation, oximeter measurements, assessment of shoulder pain, and determination of ABI, baPWV, BP, BMI, and WC will be performed (visit 4). The time points of the evaluations are presented in Table [1](#Tab1){ref-type="table"}. Table 1Study schedule of the GBH pilot study*ABI* ankle--brachial pressure index, *BaPWV* brachial--ankle pulse wave velocity, *BMI* body mass index, *GBH* Gyejibongnyeong-Hwan, *WC* waist circumference^\*^ Applies only to immediate treatment group✔ applies only to wait-list treatment group

Outcome measures {#Sec11}
----------------

### Primary outcome {#Sec12}

The primary outcome is shoulder pain. This will be assessed using VAS scores, which are the patient-reported outcome. Lower VAS scores will indicate that GBH successfully reduced shoulder pain.

### Secondary outcomes {#Sec13}

The secondary outcomes include the blood stasis score, the high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), TG, TC, fasting blood glucose (FBG), resistin, C-reactive protein (CRP), serum amyloid P (SAP), and D-dimer levels, ABI, baPWV, BP, BMI, WC, and the seven oximetry indices (SpO~2~, SpHb, PVI, SpOC, PR, SpMet, and PI). Blood stasis scores, ABI, baPWV, oximetry indexes, and levels of resistin, CRP, SAP, and D-dimer will be used to evaluate blood stasis. CRP, as an inflammation marker, will be also used as an outcome of trapezius myalgia treatment \[[@CR16]\]. HDL-C, LDL-C, TG, TC, and FBG levels, BP, BMI, and WC will be measured to verify the effectiveness of GBH for treating metabolic diseases referred to in previous studies.

Statistical analyses {#Sec14}
--------------------

All analyses will be conducted according to the intention-to-treat (ITT) principles. All statistical analyses will be two-sided, and statistical significance will be set at 0.05. The last-observation-carried-forward (LOCF) method will be used to input missing values. An independent *t* test or Wilcoxon rank-sum test will be used to compare changes in scores after performing the Kolmogorov--Smirnov test to confirm the normality of the distribution. All values will be presented as mean and standard deviation values or *n* (%) unless stated otherwise. Outcome variables will be analysed using the corresponding analysis of covariance (ANCOVA) considering the baseline scores as covariates. All statistical analyses will be performed using the SAS statistical package, version 9.4 (SAS Inc., Cary, NC, USA).

Data management and monitoring {#Sec15}
------------------------------

All data will be recorded electronically by the CRCs. All study-related data will be stored on secure servers at KIOM with frequent back-up procedures in place. Data quality will be ensured by conducting automatic validity and range checks during data entry. Both the principal investigators and the KIOM research team can access the final data sets, and all data will be password protected. The independent data monitoring team of KIOM whose members do not participate in this study will be the data monitoring committee. The trial institutions will be monitored by clinical research associates (CRAs) from KIOM while the study is ongoing; the CRAs will be independent of the research team. The CRAs will conduct monitoring visits at each site at least every 2 months after the enrolment of the first participant. They will review the source documents to confirm whether the data reported in the web-based system are complete and accurate.

Safety and adverse events {#Sec16}
-------------------------

All adverse events due to GBH will be reported in detail and participants showing any adverse event will be treated appropriately by doctors. The most common adverse reactions are expected to be skin rash, itching, anorexia, and diarrhoea. Adverse reactions will be reported to the institutional review board (IRB), and serious and unexpected adverse reactions will be reported to the regulatory authorities.

Discussion {#Sec17}
==========

The aim of this study, as a pilot trial, is to observe the clinical effectiveness of GBH. The study treatment GBH (known as Gyejibongnyeong-Hwan in Korean medicine, Gui-Zhi-Fu-Ling-Wan in traditional Chinese medicine, and Keishibukuryogan in Kampo medicine) is a herbal medicine used to eliminate blood stasis. It consists of five herbs (Cinnamomi ramulus, *W. extensa*, *P. suffruticosa* Andrews, *P. persica*, and *P. lactiflora*) \[[@CR17], [@CR18]\]. GBH has been used mainly for treating primary dysmenorrhoea, uterine myoma \[[@CR19]\], and climacteric symptoms such as hot flashes \[[@CR18]\]. A phase II trial to assess the efficacy of GBH (TU-025) Tsumura & Co (Tokyo, Japan) for hot flash management was conducted in the United States; however, the results did not show significant clinical effectiveness. GBH has also been reported to be effective in the management of metabolic diseases \[[@CR14]\]. In South Korea, GBH is one of the most popular herbal medicines for blood stasis management and has been approved as a treatment for shoulder discomfort by the MFDS \[[@CR13]\]. Since GBH has not yet been approved for hyperlipidaemia, indices related to blood lipids will be determined as secondary outcomes. Our research team has plans for further clinical trials for Investigational New Drug application, depending on the results of this pilot trial.

The outcomes used to evaluate blood stasis were also designated as study variables for this pilot trial. A blood stasis questionnaire was developed by KIOM, the results of which will be evaluated based on standard guidelines by Korean medical doctors \[[@CR20]\]. A questionnaire for blood stasis with metabolic diseases was developed and published recently \[[@CR21]\]. This is an abbreviated version of the original questionnaire; the new questionnaire comprises 15 questions (from the original 31 questions) related to metabolic diseases. The 15-item questionnaire will be used at screening, and after registration, blood stasis will be evaluated using the original questionnaire ([Appendix](#Sec19){ref-type="sec"}: Table 3). Outcomes associated with oximeter measurements and some biomarkers (i.e., resistin, CRP, SAP, and D-dimer) have been used in previous blood stasis studies and will also be measured in this pilot trial to determine whether they are associated with blood stasis. The ABI and baPWV indicate narrowing and stiffening of arteries and are therefore expected to be appropriate for the evaluation of blood stasis \[[@CR22]\].

There are some limitations to this pilot study. First, this is an open-label, wait-list controlled trial in which neither the participants nor the clinical practitioners will be blinded. We could have designed a randomised controlled trial using a placebo; however, we decided to administer GBH to both groups. Since the sample size is relatively small, we adopted a wait-list controlled design that would allow the evaluation of GBH effectiveness, without reducing the number of participants receiving GBH. Second, the outcome measures for shoulder pain are only the VAS score and the CRP level, and these may not be enough. However, this study has been designed to minimise the burden of participants and the number of patient-reported outcomes. Furthermore, the blood stasis questionnaire contains pain-related items; therefore, other measurements for shoulder pain were not included in this study, such as the Shoulder Pain and Disability Index (SPADI) and the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire \[[@CR23]\]. Third, a follow-up investigation will not be performed in the waiting group, due to the length of the entire study period and research funds. Fourth, the VAS score, which is the primary outcome, is self-reported, and there may be a measurement bias. Nonetheless, this study is meaningful because the findings of this study will serve as a reference for designing the full-scale randomised controlled trial.

Trial status {#Sec18}
------------

This document is based on version 1.5 (May 31, 2019) of the study protocol. Recruitment started on June 3, 2019, and is expected to complete by March 31, 2020. As of July 2019, five participants had been enrolled in this study and no one has yet completed the study. The trial is ongoing.

Supplementary information {#Sec20}
-------------------------

**Additional file 1.** SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.

Appendix {#Sec19}
========

Table 2Original version of the blood stasis questionnaireQuestionNoneMildModerateSevereVery severe1. Having dizziness①②③④⑤2. Having central-type palsy①②③④⑤3. Sublingual varicosities①②③④⑤4. Dark purple of palate mucosa①②③④⑤5. Blackish red gingiva①②③④⑤6. Blackish red lips①②③④⑤7. Blackish red tongue①②③④⑤8. Ecchymosis of tongue①②③④⑤9. Dark colouration of periocular region①②③④⑤10. A dark colouration of the face①②③④⑤11. Having chest pain without angina pectoris①②③④⑤12. Side pain①②③④⑤13. Tenderness and resistance of hypochondrium①②③④⑤14. Tenderness and resistance of navel region①②③④⑤15. Lower abdominal pain①②③④⑤16. Tenderness and resistance of ileocecum①②③④⑤17. Tenderness and resistance of sigmoid colon①②③④⑤18. Haemorrhoid①②③④⑤19. Dark stool①②③④⑤20. Having pain due to sprain of ankle, wrist, and spine①②③④⑤21. Having symptoms (pain, bruise) due to contusion or traffic accident①②③④⑤22. Chronic pain in joint/palsies and numbness①②③④⑤23. Stabbing pain①②③④⑤24. Pain at night①②③④⑤25. Ecchymosis of skin①②③④⑤26. Scaly and rough skin①②③④⑤27. Telangiectasia or angioectasia①②③④⑤28. Palmar erythema①②③④⑤29. Bruised easily①②③④⑤30. Angina pectoris① No② Yes31. Rough pulse① No② Yes

Table 315-item questionnaire for the diagnosis of blood stasis with metabolic diseasesQuestionResponseScore1. Angina pectorisNoYes3 points2. Having chest pain without angina pectorisNoYes3. Blackish red tongueNoYes4. Ecchymosis of tongueNoYes5. Stabbing painNoYes6. Sublingual varicositiesNoYes2 points7. Dark purple of palate mucosaNoYes8. Blackish red lipsNoYes9. Blackish red gingivaNoYes10. Chronic pain in joint/palsies and numbnessNoYes11. Pain at nightNoYes12. Bruised easilyNoYes13. Dark colouration of periocular regionNoYes1 point14. A dark colouration of the faceNoYes15. Scaly and rough skinNoYes

ABI

:   Ankle--brachial pressure index

ANCOVA

:   Analysis of covariance

baPWV

:   Brachial--ankle pulse wave velocity

BMI

:   Body mass index

BP

:   Blood pressure

CRIS

:   Clinical Research Information Service

CRP

:   C-reactive protein

FBG

:   Fasting blood glucose

GBH

:   Gyejibongnyeong-Hwan

HCG

:   Human chorionic gonadotropin

HDL-C

:   High-density lipoprotein cholesterol

ITT

:   Intention to treat

KIOM

:   Korea Institute of Oriental Medicine

LDL-C

:   Low-density lipoprotein cholesterol

LOCF

:   Last observation carried forward

MFDS

:   Ministry of Food and Drug Safety

PI

:   Perfusion index

PR

:   Pulse rate

PVI

:   Pleth variability index

SAP

:   Serum amyloid P

SpHb

:   Total haemoglobin

SpMet

:   Methaemoglobin

SpO~2~

:   Oxygen saturation

SpOC

:   Oxygen content

TC

:   Total cholesterol

TG

:   Triglyceride

VAS

:   Visual analogue scale

WC

:   Waist circumference
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